《大行》招商证券升三生制药(01530.HK)目标价至12元 评级“买入”

阿斯达克财经
31 Mar

招商证券发表研究报告指,三生制药(01530.HK) 总收入按年升17%至91.08亿元人民币,毛利率扩张1个百分点至约86%,纯利按年升34.9%。

该行料三生制药2025至2026财年收入录得双位数增长,毛利率维持至86%,同时将目标价由11元升至12元,评级“买入”。(ca/j)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-31 12:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10